Last updated: August 30, 2026
Monopril-HCT is a mature fixed-dose antihypertensive combining fosinopril sodium, an ACE inhibitor, with hydrochlorothiazide, a thiazide diuretic. Its commercial trajectory is consistent with a late-life pharmaceutical product: initial value came from combination convenience and brand recognition, while long-term revenue declined after generic competition, loss of exclusivity, therapeutic substitution, and reduced commercial support. Public filings do not report Monopril-HCT revenue separately, so a product-level financial series cannot be established from issuer disclosures. The available evidence supports a conclusion of limited current commercial value and minimal remaining patent leverage.
What is Monopril-HCT and who marketed it?
Monopril-HCT contains fosinopril sodium and hydrochlorothiazide. It was indicated for hypertension in patients who required treatment with both an ACE inhibitor and a diuretic. The product was marketed as a combination tablet in multiple strengths, including 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg formulations, subject to historical labeling and market availability.[1]
Bristol-Myers Squibb developed and marketed Monopril and Monopril-HCT. Fosinopril was part of the company’s cardiovascular franchise, which included antihypertensive and cardiovascular medicines. The combination product competed with other fixed-dose ACE inhibitor/thiazide products, including:
- Zestoretic, lisinopril/hydrochlorothiazide
- Prinzide, lisinopril/hydrochlorothiazide
- Lotensin HCT, benazepril/hydrochlorothiazide
- Capozide, captopril/hydrochlorothiazide
- Accuretic, quinapril/hydrochlorothiazide
- Avalide, irbesartan/hydrochlorothiazide
- Hyzaar, losartan/hydrochlorothiazide
The active ingredients are conventional small molecules. Monopril-HCT is not a biologic and does not face biosimilar competition. Its principal commercial risk is generic substitution.
What was the FDA regulatory status of Monopril-HCT?
Monopril-HCT received FDA approval through a new drug application for a fixed-dose combination of fosinopril sodium and hydrochlorothiazide. The product’s regulatory value rested on the combination formulation and its labeling for hypertension, rather than on a new chemical entity.
The FDA labeling identified standard ACE-inhibitor risks, including:
- Fetal toxicity and contraindication during pregnancy
- Angioedema
- Hyperkalemia
- Hypotension
- Renal impairment
- Cough
- Electrolyte and metabolic effects associated with hydrochlorothiazide
Hydrochlorothiazide added diuretic activity but also created additional monitoring requirements involving sodium, potassium, renal function, glucose, uric acid, and photosensitivity.[1]
The product is now a legacy medicine. Historical product listings and labeling remain relevant for regulatory analysis, but current commercial availability depends on manufacturer-level product status and pharmacy distribution. An FDA product being listed as discontinued does not by itself establish a safety withdrawal or regulatory failure. In mature products, discontinuation often reflects low commercial demand, portfolio rationalization, or a manufacturer’s decision to stop distributing the brand.
What patents protected Monopril-HCT?
The principal patent value associated with Monopril-HCT came from older fosinopril and fixed-dose combination patent rights. Those rights have expired or lost practical exclusivity. No meaningful current patent barrier is expected to prevent abbreviated new drug application competition for fosinopril/hydrochlorothiazide tablets.
The relevant protection categories were:
| Protection category |
Commercial role |
Current significance |
| Fosinopril compound patents |
Protected the active pharmaceutical ingredient |
Expired |
| Fosinopril salt or formulation rights |
Addressed pharmaceutical form and stability |
Expired or commercially exhausted |
| Fosinopril/hydrochlorothiazide combination claims |
Covered co-formulation and dosage combinations |
No material current exclusivity |
| Method-of-use claims |
Covered treatment of hypertension |
Weak after generic entry and labeling carve-outs |
| Manufacturing know-how |
Supported scale-up, quality, and cost control |
May remain confidential but is not a major market barrier |
Public patent databases and FDA Orange Book records should be read together because a patent’s existence does not necessarily create enforceable commercial exclusivity. The key commercial question is whether an unexpired, Orange Book-listed patent can support a Paragraph IV enforcement action. For Monopril-HCT, that pathway no longer appears to provide a meaningful branded-product defense.[2][3]
When did Monopril-HCT lose exclusivity?
Monopril-HCT lost practical exclusivity after the expiration of the relevant small-molecule and combination-product patent protections. The product is far beyond the period in which five-year new chemical entity exclusivity, three-year clinical-investigation exclusivity, or pediatric exclusivity could materially affect market entry.
The commercial transition followed the standard sequence:
- Brand launch and physician adoption.
- Expansion through combination therapy and convenience prescribing.
- Patent expiry and ANDA filings.
- Pharmacy-level generic substitution.
- Declining brand volume and reduced promotional spending.
- Product discontinuation or residual niche distribution.
An exact single “loss of exclusivity” date is less useful than the broader conclusion that Monopril-HCT is a post-exclusivity product with no meaningful remaining branded moat.
What is the Orange Book status of Monopril-HCT?
The FDA Orange Book is the principal source for determining whether an approved product has therapeutically equivalent generic competitors and whether listed patents remain relevant.[2]
For Monopril-HCT, the commercially important Orange Book questions are:
- Whether the branded NDA remains active or has been discontinued.
- Whether any ANDA products have current marketing status.
- Whether therapeutic-equivalence ratings exist for the relevant strengths.
- Whether any unexpired patents are listed against the reference product.
- Whether the product is available from the original sponsor or only through generic suppliers.
The product’s regulatory age and generic availability indicate that Orange Book status is primarily relevant to substitution and supply analysis, not to defending residual brand exclusivity. A discontinued brand can continue to influence reference-product history even when it no longer generates significant branded sales.
Which companies challenge Monopril-HCT, and are there Paragraph IV risks?
Generic competition for fosinopril/hydrochlorothiazide is based on ANDA entry rather than biosimilar litigation. Potential or historical competitors include established generic manufacturers such as Teva, Mylan, Sandoz, Lupin, and other FDA-approved suppliers, depending on the specific strength and current marketing status.
Paragraph IV risk was most relevant before the underlying patent estate expired. Under the Hatch-Waxman framework, an ANDA applicant could certify that a listed patent was invalid, unenforceable, or would not be infringed. Such a certification could trigger patent litigation and a potential 30-month stay of FDA approval under applicable conditions.[4]
That risk is now substantially diminished because:
- The product is old.
- The core active ingredients are widely genericized.
- The therapeutic category has numerous substitutes.
- The commercial value of defending the product is low.
- Any remaining formulation claim would need to be both valid and economically meaningful.
No material current Paragraph IV threat to a commercially significant Monopril-HCT franchise is evident from the product’s maturity.
What formulations are protected by Monopril-HCT patents?
The fixed-dose tablet formulation combined fosinopril sodium and hydrochlorothiazide at specific strengths. The commercial purpose was convenience, adherence, and simplified prescribing. The formulation did not create the type of complex delivery barrier associated with extended-release systems, inhalation products, transdermal systems, injectables, or drug-device combinations.
Potential formulation protections historically could have addressed:
- Ratio of fosinopril to hydrochlorothiazide
- Tablet composition
- Excipients
- Stability
- Manufacturing process
- Dissolution profile
- Specific dosage strengths
These features provide limited long-term protection when the active ingredients are conventional, the dosage form is an immediate-release tablet, and the product has extensive therapeutic substitutes. Generic manufacturers can often design around narrow formulation claims while maintaining pharmaceutical equivalence.
What method-of-use patents covered Monopril-HCT?
Monopril-HCT was used to treat hypertension. Method-of-use protection in this setting is commercially weak because hypertension is a broad, established indication and generic applicants can use label strategies that omit patented uses where appropriate.
The principal prescribing value came from the pharmacologic combination:
- Fosinopril suppresses angiotensin-converting enzyme activity.
- Hydrochlorothiazide promotes sodium and fluid excretion.
- The combination can improve blood-pressure control compared with either component alone in some patients.
Neither mechanism is proprietary today. ACE inhibitors and thiazide diuretics are both low-cost therapeutic classes with extensive clinical history.
How strong is the Monopril-HCT patent estate?
The current patent estate is weak from an investment or licensing perspective.
| Patent-estate factor |
Assessment |
| Active ingredient protection |
Expired |
| Fixed-dose combination protection |
Expired or no longer commercially decisive |
| Formulation complexity |
Low |
| Manufacturing barrier |
Low to moderate |
| Regulatory exclusivity |
Exhausted |
| Generic substitution risk |
High |
| Biosimilar risk |
Not applicable |
| Litigation leverage |
Low |
| Licensing value |
Low unless tied to a regional supply or portfolio transaction |
The remaining defensible assets, if any, are more likely to involve manufacturing know-how, supplier relationships, historical regulatory files, or geographic distribution rights than enforceable product patents.
What was the financial trajectory of Monopril-HCT?
Monopril-HCT revenue is not separately disclosed in Bristol-Myers Squibb’s public financial statements. The company historically reported broader product and business-segment performance rather than audited revenue for each dosage strength or combination product.[5]
The product’s financial trajectory can therefore be assessed through market structure:
Launch and franchise development
Early revenue benefited from the combination of an established ACE inhibitor with hydrochlorothiazide. Fixed-dose products can command a modest convenience premium and reduce pill burden. Prescribing was supported by the broader growth of ACE inhibitors in hypertension and cardiovascular-risk management.
Maturity and therapeutic substitution
Revenue pressure increased as physicians gained access to multiple ACE inhibitor/thiazide combinations and newer antihypertensive classes. Generic versions of the individual components also reduced the economic rationale for a branded combination tablet.
Post-exclusivity erosion
After generic entry, brand volume typically falls sharply because pharmacies substitute therapeutically equivalent products and payers impose higher patient costs for brands. The effect is magnified in hypertension, where treatment is chronic, alternatives are plentiful, and price sensitivity is high.
Late-life decline
The late-life product likely generated residual revenue only through limited brand prescriptions, institutional channels, or markets where generic supply was inconsistent. Reduced promotion, limited formulary access, and product discontinuation would further reduce sales.
A directional model is more supportable than a fabricated product-sales estimate:
| Period |
Revenue direction |
Main driver |
| Launch and early adoption |
Rising |
Combination convenience and brand promotion |
| Mature brand period |
Stable to declining |
Category competition and formulary pressure |
| First generic entry |
Sharp decline |
Substitution and price compression |
| Late post-exclusivity period |
Low and declining |
Generic dominance and portfolio rationalization |
| Current commercial phase |
Minimal or no meaningful branded revenue |
Discontinued or residual supply |
What market dynamics affect Monopril-HCT today?
The market is shaped by low prices, high substitution, and broad therapeutic interchangeability.
Generic competition
The most important competitors are generic fosinopril/hydrochlorothiazide products and generic alternatives containing other ACE inhibitors or angiotensin-receptor blockers. Generic manufacturers compete primarily on:
- API and manufacturing cost
- FDA compliance
- Supply reliability
- Wholesale contracts
- Pharmacy purchasing agreements
- Availability across dosage strengths
Therapeutic substitution
Prescribers can switch patients to inexpensive generic lisinopril/hydrochlorothiazide, losartan/hydrochlorothiazide, or separate fosinopril and hydrochlorothiazide tablets. This creates a low ceiling for any residual brand price.
Supply-chain economics
Fosinopril/hydrochlorothiazide is a low-complexity oral solid. Manufacturing barriers are lower than for sterile injectables, biologics, controlled-release products, or device-enabled therapies. Commercial risk therefore centers on API sourcing, quality compliance, and demand forecasting rather than production technology.
Regulatory and clinical pressure
ACE inhibitors remain clinically established, but treatment guidelines increasingly consider patient-specific factors, including kidney disease, diabetes, cardiovascular risk, electrolyte status, and tolerance. Generic availability means clinical demand for the drug class does not translate into branded demand for Monopril-HCT.[6]
What generic launch scenarios exist for Monopril-HCT?
Three scenarios describe the residual market:
- Full generic substitution. Generic fosinopril/hydrochlorothiazide products remain available across key strengths, eliminating meaningful brand economics.
- Partial supply market. One or more generic manufacturers maintain selected strengths while others are discontinued because of low margins.
- Separate-component substitution. Pharmacies and prescribers use generic fosinopril and hydrochlorothiazide as separate tablets, reducing demand for the fixed-dose product.
The first and third scenarios are the most economically damaging to the original brand. A branded relaunch would require a supply, reimbursement, or differentiation advantage that the conventional tablet formulation does not provide.
What licensing deals or litigation affect Monopril-HCT?
No major current licensing transaction or active litigation is central to the commercial outlook of Monopril-HCT. The product’s value is too mature for a conventional branded licensing strategy unless the transaction is part of a broader cardiovascular portfolio, regional rights package, or generic supply agreement.
Historical patent litigation, if any, would have been associated with ANDA filings and Paragraph IV certifications during the pre-expiration period. Current litigation exposure is limited because the core exclusivity period has ended and the product has little remaining branded revenue to protect.
How does Monopril-HCT compare with competing antihypertensive combinations?
| Product category |
Commercial position |
Competitive pressure |
| Monopril-HCT, fosinopril/HCTZ |
Mature legacy combination |
Very high |
| Lisinopril/HCTZ |
Broad generic use and low cost |
High, but strong volume |
| Losartan/HCTZ |
Generic ARB combination |
High |
| Irbesartan/HCTZ |
Generic ARB combination |
High |
| Separate ACE inhibitor plus HCTZ |
Flexible and inexpensive |
High |
| Newer branded antihypertensives |
Differentiation may remain in select segments |
Depends on patent status |
Monopril-HCT lacks a major current advantage in efficacy, delivery technology, dosing convenience, or patent protection.
Key Takeaways
- Monopril-HCT is a legacy fixed-dose combination of fosinopril sodium and hydrochlorothiazide.
- Bristol-Myers Squibb was the original major marketer.
- Its active-ingredient, formulation, and combination-product exclusivity has expired or lost practical commercial force.
- Generic substitution is the main market dynamic.
- Biosimilar risk does not apply because Monopril-HCT is a small-molecule tablet.
- Public financial filings do not isolate Monopril-HCT revenue.
- The product’s financial trajectory was likely characterized by brand growth, post-maturity decline, sharp erosion after generic entry, and minimal residual branded value.
- Current licensing, litigation, and Paragraph IV leverage appear limited.
- Any remaining economic value is more likely to arise from supply rights, regulatory files, or portfolio transactions than from patent exclusivity.
FAQs About Monopril-HCT
Is Monopril-HCT still available?
Availability depends on country, dosage strength, manufacturer, and current distributor inventory. The original branded product is a mature or discontinued product in many markets, while generic equivalents may remain available.
Is fosinopril/hydrochlorothiazide still patent protected?
The core active ingredients and conventional fixed-dose tablet technology are no longer protected by commercially meaningful exclusivity. Any residual patent must be assessed by jurisdiction and claim scope.
Can a generic company file an ANDA for Monopril-HCT?
Yes. A generic manufacturer can pursue an ANDA for an approved fosinopril/hydrochlorothiazide strength if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and other applicable conditions.
Does Monopril-HCT have biosimilar competition?
No. Biosimilars apply to biological products. Monopril-HCT is an orally administered small-molecule combination drug and is subject to generic, not biosimilar, competition.
Would a Monopril-HCT relaunch have commercial value?
A relaunch would face low pricing, established generic substitutes, limited patent protection, and weak differentiation. Commercial value would likely depend on a narrow supply opportunity or a broader cardiovascular portfolio rather than on the legacy brand alone.
References
-
U.S. Food and Drug Administration. (n.d.). Monopril-HCT (fosinopril sodium and hydrochlorothiazide) prescribing information. Drugs@FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
-
U.S. Patent and Trademark Office. (n.d.). Patent Center and patent public search. https://www.uspto.gov/
-
U.S. Food and Drug Administration. (2015). Guidance for industry: 180-day exclusivity when multiple ANDAs are submitted on the same day. FDA.
-
Bristol-Myers Squibb Company. (Various years). Annual reports and Form 10-K filings. U.S. Securities and Exchange Commission.
-
Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/ADA/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
